FDA
-
-
-
-
-
-
-
Chembio Diagnostics (CEMI) Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
-
-
-
-
-
-
-
Chembio Diagnostics (CEMI) Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System
-
-
-
-
-
-
-
Chembio Diagnostics Announces Extension of Delivery Schedule for Bio Manguinhos Purchase Order of DPP SARS-COV-2 Antigen Tests
-
-
-
-
-
-
-
Chembio Diagnostics (CEMI) Gains Said Tied to EUA for Partner
-
-
-
-
-
-
-
Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
-
-
-
-
-
-
-
Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System
-
-
-
-
-
-
-
Chembio Diagnostics (CEMI) partner LumiraDX gets FDA Emergency Use Authorization for its LumiraDx SARS-CoV-2 RNA STAR test
-
322,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

